Press
20/20 GeneSystems Enters Engagement Agreement with ClearingBid, Pioneer of the First “Crowd-Powered” Open IPOs
20/20 GeneSystems, Inc., an early market leader in multi-cancer early detection blood testing, announces that it has entered an Engagement Agreement with ClearingBid, Inc., a provider of the first platform enabling ordinary individuals and institutions to invest in IPOs at the same time, and on the same terms, as Wall Street’s largest investment firms.
20/20 GeneSystems Partners with Taiwan HealthLeader to Market OneTest in Taiwan
20/20 GeneSystems, Inc. is pleased to announce a new partnership with HealthLeader, a prominent Taiwanese healthcare provider with medical laboratories that support approximately 3,000 clinics in Taiwan, serving over 3 million people. This collaboration will bring the innovative OneTest™ cancer screening algorithm technology via a Software as a Service (SaaS) platform.
BIOINFRA and 20/20 GeneSystems Announce U.S. Technology License for Enhanced Multi-Cancer Early Detection Blood Test
BIOINFRA Life Sciences Ltd. of Korea and 20/20 GeneSystems, Inc., jointly announce the signing of an exclusive license of certain BIOINFRA technology to 20/20 for the U.S. market.
Now You Can Screen for Cancer Sooner Rather Than Later
For around $200 a test, at least one American company, 20/20 GeneSystems, Inc. (20/20), offers a MCED test called OneTest™ for Cancer.
Startup Insider: 20/20 GeneSystems Update
The First Stage Investor team sits down with Jonathan Cohen, CEO of 20/20 GeneSystems, to learn how the company has been progressing.
Inc. 5000 names Maryland’s fastest growing companies in 2022
A total of 131 Maryland businesses have been named among the fastest-growing companies in the country, according to the latest Inc. 5000 rankings.
Gaithersburg’s 20/20 GeneSystems Honored As It Opens ‘First-of-its-Kind’ Diagnostics Incubator in Montgomery County
Gaithersburg’s 20/20 GeneSystems, Inc.’s, (“20/20”), Clinical Lab InnovationAxcellerator (CLIAx), received an honorable mention in Fast Company’s 2022 World Changing Ideas Awards in the Health category. The category “honors medical innovations that save lives, extend longevity, or increase access to care.”
20/20 GeneSystems Opens ‘First-of-its-Kind’ Diagnostics Incubator in Montgomery County
Fueled by its own success and growth over the past 12 months, including the opening of a new CLIA laboratory facility in Gaithersburg, 20/20 GeneSystems is now lending a helping hand to other diagnostic startups across the area.
Fast Company Names 20/20 GeneSystems’ Diagnostics Accelerator a 2022 “World Changing Ideas” Honoree
20/20 GeneSystems, Inc.’s, (“20/20”), Clinical Lab Innovation Axcellerator (CLIAx), received an honorable mention in Fast Company’s 2022 World Changing Ideas Awards in the Health category. The category “honors medical innovations that save lives, extend longevity, or increase access to care.”
20/20 GeneSystems launches first accelerator facility for innovative clinical lab tests
20/20 GeneSystems, Inc., has announced the launch of its Clinical Lab Innovation Axcellerator (CLIAx), believed to be the first shared CLIA laboratory facility geared to helping diagnostic test innovators worldwide substantially reduce the time and cost of launching their tests in the U.S.
20/20 GeneSystems launches clinical lab innovation facility
20/20 GeneSystems has launched an innovation acceleration clinical laboratory to assist developers of diagnostic tests in getting their products to market in the U.S. more quickly and cost-effectively by using a shared laboratory space.
Accelerator Facility Launched for Clinical Lab Tests
To help diagnostics start-ups from around the world more rapidly enter the U.S. market, 20/20 GeneSystems, a clinical laboratory testing company based in Rockville, MD, has launched an accelerator facility, Clinical Lab Innovation Axcelerator (CLIAx).
First Accelerator Facility for Innovative Clinical Lab Tests
20/20 GeneSystems, Inc., (20/20), announced the launch of its Clinical Lab Innovation Axcellerator (CLIAx), believed to be the first shared CLIA laboratory facility geared to helping diagnostic test innovators worldwide substantially reduce the time and cost of launching their tests in the US.
20/20 GeneSystems Launches First Accelerator Facility for Innovative Clinical Lab Tests
20/20 GeneSystems, Inc., (“20/20”), announced the launch of itsClinical Lab Innovation Axcellerator (CLIAx), believed to be the first shared CLIA laboratory facility geared to helping diagnostic test innovators worldwide substantially reduce the time and cost of launching their tests in the U.S.
20/20 GeneSystems, Inc. Ranks No. 770 on the 2021 Inc. 5000, With Three-Year Revenue Growth of 640 Percent
Inc. magazine today revealed that 20/20 GeneSystems, Inc. is No. 770 on its annual Inc. 5000 list, the most prestigious ranking of the nation’s fastest-growing private companies
County-Based Businesses Recognized For COVID-19 Relief Efforts
These Montgomery County-based companies are being recognized by the state for their contributions to COVID-19 relief efforts.
Maryland Legislators Urge More Aggressive Use of Antibody Tests as Local Company Aims to Advance Research
Maryland Department of Health partners with 13 hospitals to launch antibody study
Only on 7: Can antibody blood tests confirm you’re immune, get you out of quarantine?
Dr. Michael Ross is on the company’s board. He says, “the beauty of it is if you have IgG, the assumption is at that point that you are protected, you’ve been exposed, i.e., you can go back to work; i.e. you can visit your grandmother.”
These 17 Maryland biotech companies are collaborating in the fight against COVID-19
As more cases of COVID-19 are being reported and leaders seek tests and treatments, biotech companies are stepping up efforts to develop new tests and treatments.
20/20 takes orders for 1st POC fingerstick COVID-19 test
BioResponse is now accepting orders for its point-of-care (POC) fingerstick blood sample rapid COVID-19 test kit
20/20 Launching First COVID-19 Rapid Antibody Test Authorized by FDA for Point-of-Care Use
20/20 BioResponse, a business unit of 20/20 GeneSystems, Inc., announced today that it is now accepting orders for the Assure COVID-19 IgG/IgM Rapid Test kits.
20/20 launching first COVID-19 rapid antibody test authorized by FDA
20/20 BioResponse, a business unit of 20/20 GeneSystems, Inc., announced today that it is now accepting orders for the Assure COVID-19 IgG/IgM Rapid Test kits. These kits were the first to receive an emergency use authorization (EUA) from the FDA for point-of-care (POC) use with fingerstick blood samples on September 23. According to the FDA
